DALLAS and NEW YORK, Nov. 24, 2014 /PRNewswire/ -- PlasmaTech Biopharmaceuticals, Inc. announced today that FINRA has approved a change of Company's stock ticker symbol.  Effective today, the Company's common shares will commence trading on the OTC Bulletin Board under the trading symbol "PTBI".  The previous trading symbol was "ACCPD."

About PlasmaTech Biopharmaceuticals, Inc.: PlasmaTech Biopharmaceuticals, Inc. (PlasmaTech) is a biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care.  Exploiting two distinct proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech is active in the development and commercialization of plasma-derived therapeutics and cancer supportive care products. The company has a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™ and multiple follow-on products in development. For more information visit www.plasmatechbio.com.

Company and Media Contact:
Christine Berni
Vice President, Corporate Development
PlasmaTech Biopharmaceuticals, Inc.
(212) 786-6208

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/plasmatech-biopharmaceuticals-inc-announces-stock-ticker-symbol-change-to-ptbi-300000047.html

SOURCE PlasmaTech Biopharmaceuticals, Inc.

Copyright 2014 PR Newswire